Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | RGS12 | O14924 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8004170 | 0.90 | ADORA2A (0.68) | ADORA2ACYP2C19MEN1KMT2ACYP2C9 | |
| SCHEMBL7993400 | 0.86 | AGER (0.63) | ADORA2ACYP2C19MEN1KMT2ACYP2C9 | |
| SCHEMBL13555314 | 0.83 | KDM4E (0.54) | ADORA2ACYP2C19KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15293582 | 0.82 | KDM4E (0.52) | ADORA2ACYP2C19MEN1KMT2ACYP2C9 | |
| SCHEMBL15293583 | 0.81 | SMN1; SMN2 (0.56) | CYP2C19MEN1KMT2ACYP2C9KDM4E | |
| SCHEMBL175217 | 0.78 | ADORA2A (0.68) | ADORA2AMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1101958 | 0.77 | MEN1 (0.75) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL27891199 | 0.77 | ADORA2A (0.67) | ADORA2AMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL171893 | 0.75 | KDM4E (0.62) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL11912010 | 0.74 | MEN1 (0.70) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | ADORA2A 1815/4885CYP2C19 4313/4885MEN1 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.